Isabelle Dessales-Guilloret

Laurel aims to analyse the features and context-dependent factors of these services, including the best innovative practices and supporting technologies. 🌐https://laurelproject.eu *************** International Foundation for Integrated Care (IFIC) | AGE Platform Europe | Eurocarers | Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | PANAXEA | EHTEL - Collaborating for Digital Health and Care in Europe | European Social Network | Social Economy Europe

8

New ERN ReCONNET webinar is scheduled for this week, on April 17th at 4pm! 💡Topic will be disease specific, targeting audience will be healthcare professionals (HCPs). Guest speaker will be Prof. Laurent Arnaud from the Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Auto-Immunes Est Sud-Ouest (RESO), Strasbourg (France). Prof. Arnaud is our Disease coordinator for Relapsing Polychondritis (RP). The webinar is focused on the French practical guidelines for the diagnosis and management of RP. RP usually begins in middle-aged individuals. This diagnosis is mainly suggested in the presence of chondritis, i.e. inflammatory flares on the cartilage, in particular of the ears, nose or respiratory tract, and more rarely in the presence of other manifestations. The formal diagnosis of relapsing polychondritis cannot be established with certainty before the onset of chondritis, which can sometimes occur several years after the first signs. No laboratory test is specific of relapsing polychondritis, the diagnosis is usually based on clinical evidence and the elimination of differential diagnoses. ✍ Registration is open and free at this link: bit.ly/49wNcYR ⚙️ More RP resources, info, and links can be found here: bit.ly/3sxN37s

10

[#Article] Check out our CaLIPSo team's article co-published in the Journal of Viral Hepatitis ! ⤵ 📰 Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather) ✒ Tangui Barré, Lucia Parlati, Fabienne Marcellin, Marc Bourlière, Clémence Ramier, Camélia Protopopescu, Vincent DI BEO, Cécile Moins, Céline Dorival-Mouly, Jérome Nicol, Jessica Zucman-Rossi, Philippe Mathurin, Dominique Larrey, Jerome Boursier, fabrice Carrat, @Patrizia Carrieri 💻 https://lnkd.in/dziBnH5y ⬇ Abstract ⬇ Although Hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAA), some cured patients face a serious risk of advanced liver damage and early mortality. In order to avoid these two negative health outcomes, it is important to identify and assess related risk factors. Little is currently known about socioeconomic and behavioural factors in this context. Using data from the ANRS CO22 Hepather cohort, we tested for associations between socioeconomic and behavioural factors and (i) advanced liver fibrosis (defined as an FIB-4 > 3.25) assessed longitudinally using a mixed-effects logistic regression model (both the whole population and stratified on advanced liver fibrosis status at the time of HCV cure) and (ii) all-cause mortality (Cox proportional hazards model), during post-HCV cure follow-up. Among 5833 participants cured of HCV, living in poverty was associated with postcure advanced liver fibrosis in participants without this diagnosis at the time of HCV cure (population attributable fraction—PAF—of 8.6%) and with mortality in the whole study population (PAF of 10.6%). The detrimental effects of unhealthy alcohol use and heavy tobacco smoking, as well as the beneficial effect of living with a stable partner were also highlighted. We highlighted the major role of poverty and behavioural factors in advanced liver fibrosis and all-cause mortality in patients cured of HCV. Encouraging linkage to social support services and healthy behaviours after successful DAA treatment could limit morbidity and increase survival in this population. #DirectActingAntivirals #HepatitisC #ChronicLiverdisease #mortality #SocioeconomicStatus Cc. Aix-Marseille Université, Inserm, IRD, ISSPAM, AP-HP, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Sorbonne Université, Université de Lille, Université d'Angers, Société Française de Santé Publique (SFSP), Collège de Liaison des Internes de Santé Publique (CLISP), EUPHA - European Public Health Association, Santé publique France

7

The Fondation ARCAD, Aide et Recherche en Cancérologie Digestive is also active internationally. 🌍 During the European #ESMO GI congress, foundations and patient organizations dedicated to digestive cancers meet in Munich 🇩🇪for a 3-day congress for Digestive Cancers Europe seminar. ✅We will have this afternoon the opportunity to meet and hear presentations on 3 topics of interest from internationally renowned Healthcare Professionals/researchers : - epidemiology of GI cancers in young Patients by Pr Cathy Eng - advances in Liver surgery for mCrC by @ Thomas gruenberger - new approachs in treating GI cancers by Myriam Chalabi #heath #oncology #cancers #GI Cyril Sarrauste de Menthiere Ghislaine Gerbier Ségolène de RETZ Laure Chotel Patients en Réseau

14

2 commentaires

💊 Antibiotic resistance is one of the most critical public health challenges of our time. 💡 This insightful article by Le Figaro highlights the growing threat, projecting 39 million deaths by 2050 due to resistant bacteria. At REVARTIS, we are committed to being part of the solution. We are proud to collaborate with Dr. Caspar Yvan and Prof. Max Maurin from the University Hospital Université Grenoble Alpes as well as Prof. Ahmed LBATH from #InstitutCarnot and Université Grenoble Alpes, in addressing this pressing issue through innovative AI solutions aimed at accelerating research and improving patient outcomes. Our partnership started in 2016 with AI-driven bacteria classification. This year, it continues with this exciting program. It is a step forward in leveraging technology, in particular #AI, to combat the resistance. If your organization is also facing challenges around healthcare or research #innovation, we’d love to connect and explore how we can assist in tackling them together. #AIforHealthcare #AntibioticResistance #HealthcareInnovation #PublicHealth #AITransformation #AI #Innovation #AIsolutions https://lnkd.in/d7HFYkua

6

For Europeans, today's date is 🇪🇺 29/05/2024. For those visiting from the USA, it's 🇺🇸 05/29/2024. Either way, today is the day that healthcare leaders from around the world are gathering in Rome for #HIMSSEurope24. At healthcare conferences in the USA, AI seems to be more prevalent, heavily featured in marketing materials. But why is the same not true in Europe? Are European nations slower to embrace change? Is language the real challenge? More focus on safety? Is there just less hype? We hope to shed some light on how Europe is actually leading a lot of the innovation, and why real applications of AI in daily healthcare are being adopted in the 🇺🇸 USA, 🇪🇺 Europe, and around the 🌏 world.

102

3 commentaires

🔥 Hot off the Press: EUFOREA's June Newsletter is here with thrilling updates to share with you! 🔍 From exciting awareness initiatives and the CRS patient guide to upcoming events, this month's edition is packed with valuable insights and opportunities for engagement! In this edition, you'll find: 📽 Free access to the full symposium recorded at the European Parliament on 17 April 2024 on 'Raising the Bar in Respiratory Care', 🎤 Exclusive interviews with leading experts in allergy and respiratory diseases, recorded at the EUFOREA Symposium, 📺 The full episode of the Global CRSwNP Awareness Day recorded on 24 April 2024, 🧑‍⚕️ Newly launched #CRS Patient Pocket Guide, 💡 Newly published paper on Nasal Polyp Syndrome: A Patient-Centred Term for CRSwNP by EUFOREA, 📎 Upcoming events 2024-2025 And more news! Stay informed, stay connected, and continue to be a part of the EUFOREA community. Click below to dive into all the exciting content we've prepared for you. Happy reading! 🔗 https://lnkd.in/edGJBchU #news #newsletter #EUFOREAN #EUFOREANnewsletter #ent #physicians #respiratorycare #respiratorydiseases #nonprofit #allergies #patients #patientcare #health #healthcare #healthprofessionals #junenews #june #brussels #belgium #editorial #euforea #crswnp #nasalpolyps #nasalsyndrome

10

Source: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians Gestational diabetes mellitus (GDM) can affect the placental transfer efficiency (PTE) of certain metal(loid)s, leading to higher concentrations of cobalt (Co), copper (Cu), gallium (Ga), and arsenic (As) in the umbilical cord blood of the GDM group. The PTE of Co showed a significant increase in the GDM group, indicating a potential link to placental abnormal angiogenesis due to GDM.

1

📃Scientific paper: Mortality associated with different influenza subtypes in France between 2015-2019;Mortalité associée aux différents sous-types de grippe en France entre 2015-2019 Abstract: Background: High levels of excess mortality during periods of active influenza circulation in France were observed in the years preceding the COVID-19 pandemic. Some of the factors that affect the rates of influenza associated mortality are influenza vaccination coverage levels in different population groups and practices for testing for influenza and related use of antiviral medications for various illness episodes (including pneumonia hospitalizations) during periods of active influenza circulation in the community. Methods: Data on sentinel ILI surveillance and sentinel virological surveillance in France were combined in a framework of a previously developed regression model to estimate the number of deaths associated with the circulation of the major influenza subtypes (A/H3N2, A/H1N1, B/Yamagata and B/Victoria) in France between 2015-2019. Results: Between week 3, 2015 and week 2, 2020, there were on average 15403 (95% CI (12591,18229)) annual influenza-associated deaths, of which 60.3% (49.9%,71.9%) were associated with influenza A/H3N2, and 29.5% (13.3%,45.5%) were associated with influenza B/Yamagata. During weeks when levels of ILI consultation in mainland France were above 50 per 100,000 persons, 7.9% (6.5%,9.4%) of all deaths in France were influenza-associated. Conclusions: High rates of influenza-associated mortality in France prior to the COVID-19 pandemic suggest that boosting influenza vaccination coverage in different population groups and testing for ... Continued on ES/IODE ➡️ https://etcse.fr/YG1kt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

1

[#Article] Check out our CaLIPSo team's article co-published in BMC Public Health⤵️ 📰 Psychometric validation of the French version of two scales measuring general (HLS19-Q12) and navigational (HLS19-NAV) health literacy using the Rasch model ✒️ Rajae TOUZANI, Alexandra Rouquette, Emilien Schultz, Cecile Allaire, Patrizia Carrieri, Julien Mancini, Jean-Benoit Hardouin 💻 https://lnkd.in/dpEHbeWs ⬇️ Abstract ⬇️ Background To examine the psychometrics properties of the French version of two scales measuring general (HLS19-Q12) and navigational (HLS19-NAV) health literacy (HL) using validation methods based on modern psychometric test theories: a Rasch model analysis. Methods The data on representative samples of the French adult population came from the Health Literacy Survey (N = 2 003), conducted in France in two waves (2020 and 2021), and from the third wave of SLAVACO study (N = 2 022), conducted in December 2021. A Rasch analysis was performed using a partial credit model with marginal maximum likelihood estimation adapted to polytomous data. Category probability curves were used to examine whether participants found it consistently difficult to distinguish between response options. Differential item functioning (DIF) was also examined for each item in the two scales as a function of age, gender, and economic status. A Person Separation Index (PSI) of 0.7 has conventionally been considered to be the minimum acceptable PSI level. Chi-square f it statistics, expressed as infit and outfit mean square statistics, were calculated for each item in the two scales. An acceptable fit corresponded to average values between 0.7 and 1.3. The dimensionality of the scales was assessed using Principal Components Analysis (PCA) on the residual correlation matrix to identify whether items are locally independent. Additionally, Smith’s method was employed to detect potential multidimensionality. Results The PSI values for both scales were greater than 0.90. No disordered categories were observed. No evidence of significant DIF was found when associated with gender and economic status. However, two items for both scales had a DIF which was dependent on age but did not have a significant impact on scale scores between younger and older people. Minor local dependence was noted on the HLS19-NAV scale. However, a PCA and Smith’s method demonstrated the unidimensionality of the French version of the scales measuring general and navigational HL. #SLAVACO #HealthLiteracy #HLS19 #RaschModel #PCM Cc. Aix-Marseille Université, Inserm, IRD, ISSPAM, Institut Paoli-Calmettes, AP-HP, Assistance Publique - Hôpitaux de Paris, Université Paris-Sud, Université Paris-Saclay, Santé publique France, APHM (Assistance Publique - Hopitaux de Marseille), Université de Tours, Société Française de Santé Publique (SFSP), Collège de Liaison des Internes de Santé Publique (CLISP), EUPHA - European Public Health Association

22

𝗣𝗥𝗢𝗙𝗜𝗗: 𝗔𝗶𝗺𝗶𝗻𝗴 𝘁𝗼 𝗥𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗥𝗶𝘀𝗸 𝗼𝗳 𝗦𝘂𝗱𝗱𝗲𝗻 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗗𝗲𝗮𝘁𝗵 #PROFID has received funding from the European Union's Horizon 2020 programme (grant agreement No 847999). The ambition of this groundbreaking research is to reassess the role of routine prophylactic ICD implantation in patients with reduced Left Ventricular Ejection Fraction (LVEF ≤ 35%) after myocardial infarction under contemporary optimal medical therapy (#OMT) and fundamentally improve clinical practice. 🏥 #PROFIDEHRA #ICD #SCD #EHRA_ESC #Horizon2020 #SuddenCardiacDeath #MedicalResearch #HealthcareInnovation  EHRA President Gerhard Hindricks

34

The second hospital university of France Hospices Civils de Lyon - HCL (HCL – CHU Lyon) is taking part to American Society of Clinical Oncology (#ASCO24) 2024, May 31 - june 4, Chicago. Several research projects led by the HCL (or in partnership) have been selected for oral presentation or poster. 📢 We look forward to meeting you on site ! 📚 Pr Michael Duruisseaux Clinical Science Symposium – Lung cancer – Targeting KRAS in non-small cell lung cancer – 1 juin 13h15 – Hall B1 Abstract#LBA8509 - KRYSTAL-12 : phase 3 study of adagrasib versus docetaxel in patients with previous treated advanced/metastasic non-small cell lung cancer (NSCLC) harboring a KRAS-G12C mutation. TonyS.K Mok, MD, FRCPC, FASCO Poster session - Lung cancer – Non-Small cell metastasic - 3 juin Hall A Abstract #8614 - Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model - Michaël Duruisseaux, MD,PhD Abstract #8647 - Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer – Mihaela Aldea, MD, PhD Abstract#8604 - Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLCC) - Jie Wang, MD 📚 Pr Benoit You Poster session - Gynecologic Cancer Abstract #5560 - Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian hashtag #cancers in two large independent datasets. Abstract #5605 - Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial. Gilles Freyer Abstract #TPS3635 - BreAK CRC, a first-in-human phase I/II trial of STC-1010, a new allogenic cancer vaccine for advanced or metastatic unresectable colorectal cancer. 📚 Pr Olivier Glehen Education Session - Thinking Outside the Box: Management of Limited Metastatic Colorectal Cancer Debulking and Hyperthermic Intraperitoneal hashtag #Chemotherapy Connection: A Winning Strategy? – Olivier Glehen MD,PhD Session publication only – Gastrointestinal cancer, colorectal and anal Abstract#e15561 – PIPOX : hashtag #PIPAC in patients with peritoneal metastases from gastrointestinal tract - F Dumont 📚 Pr Stéphane Dalle Poster session Abstract #9524 Poster BD#308 - Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years Abstract #9521 – Poster Bd #305 - When to stop immunotherapy for advanced melanoma: Emulation of target trials Oral abstract session Abstract #9506 - Triplet Combination Treatments With Pembrolizumab for Anti–PD-(L)1–Refractory Advanced hashtag #Melanoma: Preliminary Results of the Phase 1/2 KEYMAKER-U02A

155

2 commentaires